Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity

a technology which is applied in the field of pyrimidine and pyridine compounds, can solve the problems of difficult to develop a reversible inhibitor that selectively inhibits a desired (la, target) kinase, difficult to maintain inhibition over extended periods of time, and high dosages

Inactive Publication Date: 2017-05-04
MERCK PATENT GMBH
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is about new chemicals that can treat and prevent cancer, specifically Non-Hodgkin's Lymphoma (NHL) and Non-Hodgkin's Lymphoma Diffuse Large B-cell Lymphoma (DLBCL). The chemicals have a specific formula and can target specific types of cancer cells. This patent is important for developing new treatments for these diseases.

Problems solved by technology

Given the structure of the ATP-binding sites are highly conserved among kinases, it has been difficult to develop a reversible inhibitor that selectively inhibits a desired (La, target) kinase.
Moreover, given that many reversible kinase inhibitors readily dissociate from their target polypeptide(s), maintaining inhibition over extended periods of time can be difficult.
When using reversible kinase inhibitors as therapeutics, therefore, often times near toxic dosages and / or frequent dosing is required to achieve the intended biological effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity
  • Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity
  • Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity

Examples

Experimental program
Comparison scheme
Effect test

example 1

Mosaic Spot Assay (CLL Patient Samples)

[0175]The Mosaic Spot Assay was conducted in accordance with Mosaic Laboratories' SOPs. The CLL blood and bone marrow mononuclear cells were evaluated for viability and cell count prior to plating in Mosaic Spot Media (X-Vivo 10 Media [Lonza, Fisher Scientific, Carlsbad, Calif.]+10% FBS [Life Technologies, Carlsbad, Calif.]) in a 96-well cytophobic plate in the presence of compounds and two controls: 1) a cytotoxic dose of cisplatin serving as a positive control; and 2) no drug treatment serving as a reference and negative control. Tumor cells were placed in a humidified 37° C. incubator with 5% CO2 for 4 days. At the end of the incubation, cells were removed and cytocentrifuged onto positive charged glass slides (Superfrost+, VWR, Radnor, Pa.). Slides were stained with Wright Giemsa in accordance with Mosaic Laboratories SOPs. Cell growth was measured by a hematopathologist. The results are provided in FIG. 1.

example 2

MCL / ABC-DLBCL Cell Lines

[0176]Cell lines that were preserved in liquid nitrogen were thawed and expanded in growth media containing full serum. Once cells reached expected doubling times, screening began. Cells were seeded in growth media in black 384-well tissue culture treated plates. Cells were equilibrated in assay plates via centrifugation and placed in incubators (attached to the Dosing Modules) at 37° C. for twenty-four hours before treatment. At the time of treatment, a set of assay plates (which do not receive treatment) were collected and ATP levels were measured by adding ATPLite (Perkin Elmer). These Tzero (T0) plates were read using ultra-sensitive luminescence on Envision plate readers. Assay plates were incubated with compound for seventy-two hours and were analyzed using ATPLite. All data points were collected via automated processes and were subject to quality control and analyzed using Horizon's proprietary software. Assay plates were accepted if they passed the fo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Forceaaaaaaaaaa
Forceaaaaaaaaaa
Forceaaaaaaaaaa
Login to View More

Abstract

The present invention provides methods of treating cancer using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK).

Description

RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional applications U.S. Ser. No. 62 / 250,575, filed on Nov. 4, 2015, U.S. Ser. No. 62 / 296,143, filed on Feb. 17, 2016, and U.S. Ser. No. 62 / 341,189, filed on May 25, 2016, the contents of which are incorporated herein by reference, in their entireties.FIELD OF THE INVENTION[0002]The invention relates to a series of pyrimidine and pyridine compounds that are useful as therapeutics in the treatment of cancer in mammals. More particularly, embodiments of the present invention describe irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase (hereinafter referred to as: “BTK”). Methods for the preparation of the aforementioned compounds are disclosed in addition to the incorporation of these compounds into pharmaceutical compositions that include the same.BACKGROUND[0003]Protein kinases constitute a large family of structurally related enzymes that are responsible for t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/506A61K31/55A61K31/5377A61K31/505A61K31/69
CPCA61K31/506A61K31/505A61K31/55A61K31/5377A61K31/69A61P35/00C07D401/12
Inventor HUCK, BAYARD R.GOODSTAL, SAMANTHA M.GIMMI-MCKIM, CLAUDE
Owner MERCK PATENT GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com